Energenesis Biomedical Co. Ltd.

Energenesis Biomedical Co., Ltd. is a biomedicine company based in Taipei, Taiwan, founded in 2012. Its pipeline includes ENERGI-F703, in Phase III trials for diabetic foot ulcers, and ENERGI-F701, a topical alopecia treatment in Phase II trials. Other candidates include ENERGI-F711 (burn cream), ENERGI-F703VLU (venous leg ulcer gel), ENERGI-F703EB (topical cream for hereditary epidermolysis bullosa wounds), ENERGI-F702 (metabolic diseases), ENERGI-F704 (inflammatory bowel disease), ENERGI-F708 (asthma), ENERGI-F705 (Parkinson's disease), ENERGI-F707 (mitochondria deficiency), ENERGI-F706 (cachexia), ENERGI-F709 (vaccine adjuvant), and ENERGI-F710 (blood phosphate control). The company also offers scientific products such as western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions.